Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy
Authors:
- M.E GoreMGM.E Gore
- 1 March 2000
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 36 (4) , 503-507
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinomaAnnals of Oncology, 1997
- Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxicAnnals of Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995
- Impact of doxorubicin on survival in advanced ovarian cancer.Journal of Clinical Oncology, 1995
- Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.Journal of Clinical Oncology, 1994
- Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of Clinical Oncology, 1993
- New cytostatic drugs in ovarian cancerAnnals of Oncology, 1993
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991
- Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1991